H-ras, N-ras, and K-ras are canonical ras gene family members frequently activated by point mutation in human cancers and coding for 4 different, highly related protein isoforms (H-Ras, N-Ras, K-Ras4A, and K-Ras4B). Their expression is nearly ubiquitous and broadly conserved across eukaryotic species, although there are quantitative and qualitative differences of expression depending on the tissue and/or developmental stage under consideration. Extensive functional studies have determined during the last quarter century that these Ras gene products are critical components of signaling pathways that control eukaryotic cell proliferation, survival, and differentiation. However, because of their homology and frequent coexpression in various cellular contexts, it remained unclear whether the different Ras proteins play specific or overlapping functional roles in physiological and pathological processes. Initially, their high degree of sequence homology and the observation that all Ras isoforms share common sets of downstream effectors and upstream activators suggested that they were mostly redundant functionally. In contrast, the notion of functional specificity for each of the different Ras isoforms is supported at present by an increasing body of experimental observations, including 1) the fact that different ras isoforms are preferentially mutated in specific types of tumors or developmental disorders; 2) the different transforming potential of transfected ras genes in different cell contexts; 3) the distinct sensitivities exhibited by the various Ras family members for modulation by different GAPs or GEFs; 4) the demonstration that different Ras isoforms follow distinct intracellular processing pathways and localize to different membrane microdomains or subcellular compartments; 5) the different phenotypes displayed by genetically modified animal strains for each of the 3 ras loci; and 6) the specific transcriptional networks controlled by each isoform in different cellular settings.
Reuther GW,Der CJ.The Ras branch of small GTPases: Ras family members don’t fall far from the tree.Curr Opin Cell Biol. 2000;12:157-65
6.
Field J,Broek D,Kataoka T,Wigler M.Guanine nucleotide activation of, and competition between, RAS proteins from Saccharomyces cerevisiae.Mol Cell Biol. 1987;7:2128-33
7.
Hall BE,Yang SS,Boriack-Sjodin PA,Kuriyan J,Bar-Sagi D.Structure-based mutagenesis reveals distinct functions for Ras switch 1 and switch 2 in Sos-catalyzed guanine nucleotide exchange.J Biol Chem. 2001;276:27629-37
8.
Herrmann C.Ras-effector interactions: after one decade.Curr Opin Struct Biol. 2003;13:122-9
9.
Ma J,Karplus M.Molecular switch in signal transduction: reaction paths of the conformational changes in ras p21.Proc Natl Acad Sci U S A. 1997;94:11905-10
10.
Satoh T,Nakamura S,Kaziro Y.Induction of neurite formation in PC12 cells by microinjection of proto-oncogenic Ha-ras protein preincubated with guanosine-5’-O-(3-thiotriphosphate).Mol Cell Biol. 1987;7:4553-6
11.
Wittinghofer A,Pai EF.The structure of Ras protein: a model for a universal molecular switch.Trends Biochem Sci. 1991;16:382-7
12.
Milburn MV,Tong L,deVos AM, et al.Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins.Science. 1990;247:939-45
13.
Schlichting I,Almo SC,Rapp G, et al.Time-resolved X-ray crystallographic study of the conformational change in Ha-Ras p21 protein on GTP hydrolysis.Nature. 1990;345:309-15
Bos JL.ras oncogenes in human cancer: a review.Cancer Res. 1989;49:4682-9
16.
Broach JR,Deschenes RJ.The function of ras genes in Saccharomyces cerevisiae.Adv Cancer Res. 1990;54:79-139
17.
Hancock JF.Ras proteins: different signals from different locations.Nat Rev Mol Cell Biol. 2003;4:373-84
18.
Hancock JF,Cadwallader K,Paterson H,Marshall CJ.A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins.EMBO J. 1991;10:4033-9
19.
Leon J,Guerrero I,Pellicer A.Differential expression of the ras gene family in mice.Mol Cell Biol. 1987;7:1535-40
20.
Roy S,Luetterforst R,Harding A, et al.Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains.Nat Cell Biol. 1999;1:98-105
21.
Roy S,Plowman S,Rotblat B, et al.Individual palmitoyl residues serve distinct roles in H-ras trafficking, microlocalization, and signaling.Mol Cell Biol. 2005;25:6722-33
22.
Su AI,Wiltshire T,Batalov S, et al.A gene atlas of the mouse and human protein-encoding transcriptomes.Proc Natl Acad Sci U S A. 2004;101:6062-7
23.
Bar-Sagi D.A Ras by any other name.Mol Cell Biol. 2001;21:1441-3
24.
Lowy DR,Willumsen BM.Function and regulation of ras.Annu Rev Biochem. 1993;62:851-91
25.
Plowman SJ,Hancock JF.Ras signaling from plasma membrane and endomembrane microdomains.Biochim Biophys Acta. 2005;1746:274-83
26.
Rojas JM,Santos E.ras genes and human cancer: different implications and different roles.Curr Genomics. 2002;3:295-311
27.
Furth ME,Aldrich TH,Cordon-Cardo C.Expression of ras proto-oncogene proteins in normal human tissues.Oncogene. 1987;1:47-58
28.
Fiorucci G,Hall A.All three human ras genes are expressed in a wide range of tissues.Biochim Biophys Acta. 1988;950:81-3
29.
Bos JL.The ras gene family and human carcinogenesis.Mutat Res. 1988;195:255-71
30.
Der CJ,Finkel T,Cooper GM.Biological and biochemical properties of human rasH genes mutated at codon 61.Cell. 1986;44:167-76
31.
Downward J.Targeting RAS signalling pathways in cancer therapy.Nat Rev Cancer. 2003;3:11-22
32.
Raptis L,Brownell HL,Corbley MJ,Wood KW,Wang D,Haliotis T.Cellular ras gene activity is required for full neoplastic transformation by the large tumor antigen of SV40.Cell Growth Differ. 1997;8:891-901
33.
Hirakawa T,Ruley HE.Rescue of cells from ras oncogene-induced growth arrest by a second, complementing, oncogene.Proc Natl Acad Sci U S A. 1988;85:1519-23
34.
Land H,Parada LF,Weinberg RA.Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes.Nature. 1983;304:596-602
35.
Ruley HE.Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture.Nature. 1983;304:602-6
36.
Land H,Parada LF,Weinberg RA.Cellular oncogenes and multistep carcinogenesis.Science. 1983;222:771-8
37.
Ward JM,Perantoni AO,Santos E.Comparative immunohistochemical reactivity of monoclonal and polyclonal antibodies to H-ras p21 in normal and neoplastic tissues of rodents and humans.Oncogene. 1989;4:203-13
38.
Chesa PG,Rettig WJ,Melamed MR,Old LJ,Niman HL.Expression of p21ras in normal and malignant human tissues: lack of association with proliferation and malignancy.Proc Natl Acad Sci U S A. 1987;84:3234-8
Rochlitz CF,Scott GK,Dodson JM, et al.Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer.Cancer Res. 1989;49:357-60
48.
Tartaglia M,Gelb BD.Noonan syndrome and related disorders: genetics and pathogenesis.Annu Rev Genomics Hum Genet. 2005;6:45-68
Pells S,Divjak M,Romanowski P, et al.Developmentally-regulated expression of murine K-ras isoforms.Oncogene. 1997;15:1781-6
51.
Muller R,Slamon DJ,Adamson ED, et al.Transcription of c-onc genes c-rasKi and c-fms during mouse development.Mol Cell Biol. 1983;3:1062-9
52.
Thapar R,Williams JG,Campbell SL.NMR characterization of full-length farnesylated and non-farnesylated H-Ras and its implications for Raf activation.J Mol Biol. 2004;343:1391-408
53.
Ellis CA,Clark G.The importance of being K-Ras.Cell Signal. 2000;12:425-34
54.
Hancock JF,Magee AI,Childs JE,Marshall CJ.All ras proteins are polyisoprenylated but only some are palmitoylated.Cell. 1989;57:1167-77
55.
Hancock JF,Paterson H,Marshall CJ.A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane.Cell. 1990;63:133-9
56.
Matallanas D,Sanz-Moreno V,Arozarena I, et al.Distinct utilization of effectors and biological outcomes resulting from site-specific Ras activation: Ras functions in lipid rafts and Golgi complex are dispensable for proliferation and transformation.Mol Cell Biol. 2006;26:100-16
57.
Prior IA,Hancock JF.Compartmentalization of Ras proteins.J Cell Sci. 2001;114:1603-8
58.
Prior IA,Muncke C,Parton RG,Hancock JF.Direct visualization of Ras proteins in spatially distinct cell surface microdomains.J Cell Biol. 2003;160:165-70
59.
Willumsen BM,Christensen A,Hubbert NL,Papageorge AG,Lowy DR.The p21 ras C-terminus is required for transformation and membrane association.Nature. 1984;310:583-6
60.
Hancock JF,Parton RG.Ras plasma membrane signalling platforms.Biochem J. 2005;389:1-11
61.
Chiu VK,Bivona T,Hach A, et al.Ras signalling on the endoplasmic reticulum and the Golgi.Nat Cell Biol. 2002;4:343-50
62.
Bivona TG,Quatela SE,Bodemann BO, et al.PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis.Mol Cell. 2006;21:481-93
63.
Kinzler KW,Vogelstein B.Lessons from hereditary colorectal cancer.Cell. 1996;87:159-70
64.
Garcia-Rostan G,Zhao H,Camp RL, et al.ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.J Clin Oncol. 2003;21:3226-35
65.
Portier M,Moles JP,Mazars GR, et al.p53 and RAS gene mutations in multiple myeloma.Oncogene. 1992;7:2539-43
66.
Kraus MH,Yuasa Y,Aaronson SA.A position 12-activated H-ras oncogene in all HS578T mammary carcinosarcoma cells but not normal mammary cells of the same patient.Proc Natl Acad Sci U S A. 1984;81:5384-8
67.
Schubbert S,Shannon K,Bollag G.Hyperactive Ras in developmental disorders and cancer.Nat Rev Cancer. 2007;7:295-308
68.
Hennekam RC.Costello syndrome: an overview.Am J Med Genet C Semin Med Genet. 2003;117C:42-8
69.
Schubbert S,Zenker M,Rowe SL, et al.Germline KRAS mutations cause Noonan syndrome.Nat Genet. 2006;38:331-6
70.
Carta C,Pantaleoni F,Bocchinfuso G, et al.Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype.Am J Hum Genet. 2006;79:129-35
71.
Zenker M,Lehmann K,Schulz AL, et al.Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations.J Med Genet. 2007;44:131-5
72.
Aoki Y,Niihori T,Kawame H, et al.Germline mutations in HRAS proto-oncogene cause Costello syndrome.Nat Genet. 2005;37:1038-40
73.
Estep AL,Tidyman WE,Teitell MA,Cotter PD,Rauen KA.HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy.Am J Med Genet A. 2006;140:8-16
74.
Gripp KW,Lin AE,Stabley DL, et al.HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation.Am J Med Genet A. 2006;140:1-7
75.
Kerr B,Delrue MA,Sigaudy S, et al.Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases.J Med Genet. 2006;43:401-5
76.
Zampino G,Pantaleoni F,Carta C, et al.Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome.Hum Mutat. 2007;28:265-72
77.
Oliveira JB,Bidere N,Niemela JE, et al.NRAS mutation causes a human autoimmune lymphoproliferative syndrome.Proc Natl Acad Sci U S A. 2007;104:8953-8
78.
Cheng CM,Li H,Gasman S,Huang J,Schiff R,Chang EC.Compartmentalized Ras proteins transform NIH 3T3 cells with different efficiencies.Mol Cell Biol. 2011;31:983-97
79.
Maher J,Baker DA,Manning M,Dibb NJ,Roberts IA.Evidence for cell-specific differences in transformation by N-, H- and K-ras.Oncogene. 1995;11:1639-47
Oliva JL,Zarich N,Martinez N, et al.The P34G mutation reduces the transforming activity of K-Ras and N-Ras in NIH 3T3 cells but not of H-Ras.J Biol Chem. 2004;279:33480-91
82.
Parikh C,Subrahmanyam R,Ren R.Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.Cancer Res. 2007;67:7139-46
83.
Katzav S,Packham G,Sutherland M,Aroca P,Santos E,Cleveland JL.Vav and Ras induce fibroblast transformation by overlapping signaling pathways which require c-Myc function.Oncogene. 1995;11:1079-88
84.
Ruiz S,Santos E,Bustelo XR.RasGRF2, a guanosine nucleotide exchange factor for Ras GTPases, participates in T-cell signaling responses.Mol Cell Biol. 2007;27:8127-42
85.
Ruiz S,Santos E,Bustelo XR.The use of knockout mice reveals a synergistic role of the Vav1 and Rasgrf2 gene deficiencies in lymphomagenesis and metastasis.PLoS One. 2009;4:e8229
86.
Fotiadou PP,Takahashi C,Rajabi HN,Ewen ME.Wild-type NRas and KRas perform distinct functions during transformation.Mol Cell Biol. 2007;27:6742-55
87.
Hamilton M,Wolfman A.Ha-ras and N-ras regulate MAPK activity by distinct mechanisms in vivo.Oncogene. 1998;16:1417-28
88.
Haigis KM,Kendall KR,Wang Y, et al.Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.Nat Genet. 2008;40:600-8
89.
Nobes CD,Hall A.Rho GTPases control polarity, protrusion, and adhesion during cell movement.J Cell Biol. 1999;144:1235-44
90.
Voice JK,Klemke RL,Le A,Jackson JH.Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility.J Biol Chem. 1999;274:17164-70
91.
Walsh AB,Bar-Sagi D.Differential activation of the Rac pathway by Ha-Ras and K-Ras.J Biol Chem. 2001;276:15609-15
92.
Hall A.Rho GTPases and the actin cytoskeleton.Science. 1998;279:509-14
93.
Yan Z,Deng X,Chen M, et al.Oncogenic c-Ki-ras but not oncogenic c-Ha-ras up-regulates CEA expression and disrupts basolateral polarity in colon epithelial cells.J Biol Chem. 1997;272:27902-7
94.
Finkelstein SD,Sayegh R,Bakker A,Swalsky P.Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis.Arch Surg. 1993;128:526-31
95.
Suchy B,Zietz C,Rabes HM.K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis.Int J Cancer. 1992;52:30-3
96.
Bar-Sagi D,Feramisco JR.Microinjection of the ras oncogene protein into PC12 cells induces morphological differentiation.Cell. 1985;42:841-8
97.
Benito M,Porras A,Nebreda AR,Santos E.Differentiation of 3T3-L1 fibroblasts to adipocytes induced by transfection of ras oncogenes.Science. 1991;253:565-8
98.
Qui MS,Green SH.PC12 cell neuronal differentiation is associated with prolonged p21ras activity and consequent prolonged ERK activity.Neuron. 1992;9:705-17
99.
Schulz WA.Understanding urothelial carcinoma through cancer pathways.Int J Cancer. 2006;119:1513-8
Bauer J,Curtin JA,Pinkel D,Bastian BC.Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations.J Invest Dermatol. 2007;127:179-82
102.
Ganguly S,Murty VV,Samaniego F,Reuter VE,Bosl GJ,Chaganti RS.Detection of preferential NRAS mutations in human male germ cell tumors by the polymerase chain reaction.Genes Chromosomes Cancer. 1990;1:228-32
103.
Parikh C,Subrahmanyam R,Ren R.Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.Blood. 2006;108:2349-57
104.
Quinlan MP,Quatela SE,Philips MR,Settleman J.Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion.Mol Cell Biol. 2008;28:2659-74
105.
Quinlan MP,Settleman J.Isoform-specific ras functions in development and cancer.Future Oncol. 2009;5:105-16
Yamaguchi-Iwai Y,Satake M,Murakami Y,Sakai M,Muramatsu M,Ito Y.Differentiation of F9 embryonal carcinoma cells induced by the c-jun and activated c-Ha-ras oncogenes.Proc Natl Acad Sci U S A. 1990;87:8670-4
109.
Omerovic J,Hammond DE,Clague MJ,Prior IA.Ras isoform abundance and signalling in human cancer cell lines.Oncogene. 2008;27:2754-62
110.
Bollag G,McCormick F.Differential regulation of rasGAP and neurofibromatosis gene product activities.Nature. 1991;351:576-9
111.
Clyde-Smith J,Silins G,Gartside M, et al.Characterization of RasGRP2, a plasma membrane-targeted, dual specificity Ras/Rap exchange factor.J Biol Chem. 2000;275:32260-7
112.
Jones MK,Jackson JH.Ras-GRF activates Ha-Ras, but not N-Ras or K-Ras 4B, protein in vivo.J Biol Chem. 1998;273:1782-7
113.
Liao J,Wolfman JC,Wolfman A.K-ras regulates the steady-state expression of matrix metalloproteinase 2 in fibroblasts.J Biol Chem. 2003;278:31871-8
114.
Mitin NY,Ramocki MB,Zullo AJ,Der CJ,Konieczny SF,Taparowsky EJ.Identification and characterization of rain, a novel Ras-interacting protein with a unique subcellular localization.J Biol Chem. 2004;279:22353-61
115.
Plowman SJ,Muncke C,Parton RG,Hancock JF.H-ras, K-ras, and inner plasma membrane raft proteins operate in nanoclusters with differential dependence on the actin cytoskeleton.Proc Natl Acad Sci U S A. 2005;102:15500-5
116.
Villalonga P,Lopez-Alcala C,Bosch M, et al.Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling.Mol Cell Biol. 2001;21:7345-54
117.
Vos MD,Ellis CA,Elam C,Ulku AS,Taylor BJ,Clark GJ.RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor.J Biol Chem. 2003;278:28045-51
118.
Yan J,Roy S,Apolloni A,Lane A,Hancock JF.Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase.J Biol Chem. 1998;273:24052-6
119.
Ehrhardt A,David MD,Ehrhardt GR,Schrader JW.Distinct mechanisms determine the patterns of differential activation of H-Ras, N-Ras, K-Ras 4B, and M-Ras by receptors for growth factors or antigen.Mol Cell Biol. 2004;24:6311-23
120.
Hamilton M,Wolfman A.Oncogenic Ha-Ras-dependent mitogen-activated protein kinase activity requires signaling through the epidermal growth factor receptor.J Biol Chem. 1998;273:28155-62
121.
Rocks O,Peyker A,Bastiaens PI.Spatio-temporal segregation of Ras signals: one ship, three anchors, many harbors.Curr Opin Cell Biol. 2006;18:351-7
122.
Rocks O,Peyker A,Kahms M, et al.An acylation cycle regulates localization and activity of palmitoylated Ras isoforms.Science. 2005;307:1746-52
123.
Matallanas D,Arozarena I,Berciano MT, et al.Differences on the inhibitory specificities of H-Ras, K-Ras, and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization.J Biol Chem. 2003;278:4572-81
124.
Jaumot M,Yan J,Clyde-Smith J,Sluimer J,Hancock JF.The linker domain of the Ha-Ras hypervariable region regulates interactions with exchange factors, Raf-1 and phosphoinositide 3-kinase.J Biol Chem. 2002;277:272-8
125.
Rosseland CM,Wierod L,Flinder LI,Oksvold MP,Skarpen E,Huitfeldt HS.Distinct functions of H-Ras and K-Ras in proliferation and survival of primary hepatocytes due to selective activation of ERK and PI3K.J Cell Physiol. 2008;215:818-26
126.
Whitehead IP,Campbell S,Rossman KL,Der CJ.Dbl family proteins.Biochim Biophys Acta. 1997;1332:F1-23
127.
Hyvonen M,Macias MJ,Nilges M,Oschkinat H,Saraste M,Wilmanns M.Structure of the binding site for inositol phosphates in a PH domain.EMBO J. 1995;14:4676-85
128.
Lemmon MA,Ferguson KM,O’Brien R,Sigler PB,Schlessinger J.Specific and high-affinity binding of inositol phosphates to an isolated pleckstrin homology domain.Proc Natl Acad Sci U S A. 1995;92:10472-6
129.
Rebecchi MJ,Scarlata S.Pleckstrin homology domains: a common fold with diverse functions.Annu Rev Biophys Biomol Struct. 1998;27:503-28
130.
Millan O,Ballester A,Castrillo A, et al.H-Ras-specific activation of NF-kappaB protects NIH 3T3 cells against stimulus-dependent apoptosis.Oncogene. 2003;22:477-83
131.
Oliva JL,Perez-Sala D,Castrillo A, et al.The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and activates H-Ras.Proc Natl Acad Sci U S A. 2003;100:4772-7
132.
Lowy DR,Willumsen BM.Protein modification: new clue to Ras lipid glue.Nature. 1989;341:384-5
133.
Ulsh LS,Shih TY.Metabolic turnover of human c-rasH p21 protein of EJ bladder carcinoma and its normal cellular and viral homologs.Mol Cell Biol. 1984;4:1647-52
134.
Laude AJ,Prior IA.Palmitoylation and localisation of RAS isoforms are modulated by the hypervariable linker domain.J Cell Sci. 2008;121:421-7
135.
Casey PJ,Solski PA,Der CJ,Buss JE.p21ras is modified by a farnesyl isoprenoid.Proc Natl Acad Sci U S A. 1989;86:8323-7
136.
Gutierrez L,Magee AI,Marshall CJ,Hancock JF.Post-translational processing of p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis.EMBO J. 1989;8:1093-8
137.
Choy E,Chiu VK,Silletti J, et al.Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi.Cell. 1999;98:69-80
138.
Dai Q,Choy E,Chiu V, et al.Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum.J Biol Chem. 1998;273:15030-4
139.
Kim E,Ambroziak P,Otto JC, et al.Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells.J Biol Chem. 1999;274:8383-90
140.
Apolloni A,Prior IA,Lindsay M,Parton RG,Hancock JF.H-ras but not K-ras traffics to the plasma membrane through the exocytic pathway.Mol Cell Biol. 2000;20:2475-87
141.
Choy E,Philips M.Green fluorescent protein-tagged Ras proteins for intracellular localization.Methods Enzymol. 2001;332:50-64
142.
Omerovic J,Prior IA.Compartmentalized signalling: Ras proteins and signalling nanoclusters.FEBS J. 2009;276:1817-25
143.
Gomez GA,Daniotti JL.H-Ras dynamically interacts with recycling endosomes in CHO-K1 cells: involvement of Rab5 and Rab11 in the trafficking of H-Ras to this pericentriolar endocytic compartment.J Biol Chem. 2005;280:34997-5010
144.
Goodwin JS,Drake KR,Remmert CL,Kenworthy AK.Ras diffusion is sensitive to plasma membrane viscosity.Biophys J. 2005;89:1398-410
145.
Baker TL,Zheng H,Walker J,Coloff JL,Buss JE.Distinct rates of palmitate turnover on membrane-bound cellular and oncogenic H-ras.J Biol Chem. 2003;278:19292-300
146.
Magee AI,Gutierrez L,McKay IA,Marshall CJ,Hall A.Dynamic fatty acylation of p21N-ras.EMBO J. 1987;6:3353-7
147.
Thissen JA,Gross JM,Subramanian K,Meyer T,Casey PJ.Prenylation-dependent association of Ki-Ras with microtubules: evidence for a role in subcellular trafficking.J Biol Chem. 1997;272:30362-70
148.
Chen Z,Otto JC,Bergo MO,Young SG,Casey PJ.The C-terminal polylysine region and methylation of K-Ras are critical for the interaction between K-Ras and microtubules.J Biol Chem. 2000;275:41251-7
149.
Prior IA,Harding A,Yan J,Sluimer J,Parton RG,Hancock JF.GTP-dependent segregation of H-ras from lipid rafts is required for biological activity.Nat Cell Biol. 2001;3:368-75
150.
McLaughlin S,Hangyas-Mihalyne G,Zaitseva I,Golebiewska U.Reversible - through calmodulin - electrostatic interactions between basic residues on proteins and acidic lipids in the plasma membrane.Biochem Soc Symp. 2005;72:189-98
151.
Fivaz M,Meyer T.Reversible intracellular translocation of KRas but not HRas in hippocampal neurons regulated by Ca2+/calmodulin.J Cell Biol. 2005;170:429-41
152.
Levkowitz G,Waterman H,Zamir E, et al.c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor.Genes Dev. 1998;12:3663-74
Mor A,Philips MR.Compartmentalized Ras/MAPK signaling.Annu Rev Immunol. 2006;24:771-800
155.
Traverse S,Gomez N,Paterson H,Marshall C,Cohen P.Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells: comparison of the effects of nerve growth factor and epidermal growth factor.Biochem J. 1992;288 (Pt 2): 351-5
Guil S,de La Iglesia N,Fernandez-Larrea J, et al.Alternative splicing of the human proto-oncogene c-H-ras renders a new Ras family protein that trafficks to cytoplasm and nucleus.Cancer Res. 2003;63:5178-87
158.
Wolfman JC,Planchon SM,Liao J,Wolfman A.Structural and functional consequences of c-N-Ras constitutively associated with intact mitochondria.Biochim Biophys Acta. 2006;1763:1108-24
159.
Rebollo A,Perez-Sala D,Martinez AC.Bcl-2 differentially targets K-, N-, and H-Ras to mitochondria in IL-2 supplemented or deprived cells: implications in prevention of apoptosis.Oncogene. 1999;18:4930-9
160.
de la Vega M,Burrows JF,McFarlane C,Govender U,Scott CJ,Johnston JA.The deubiquitinating enzyme USP17 blocks N-Ras membrane trafficking and activation but leaves K-Ras unaffected.J Biol Chem. 2010;285:12028-36
161.
Sinn E,Muller W,Pattengale P,Tepler I,Wallace R,Leder P.Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo.Cell. 1987;49:465-75
162.
Jackson EL,Willis N,Mercer K, et al.Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.Genes Dev. 2001;15:3243-8
163.
Meuwissen R,Linn SC,van der Valk M,Mooi WJ,Berns A.Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene.Oncogene. 2001;20:6551-8
164.
Guerra C,Mijimolle N,Dhawahir A, et al.Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context.Cancer Cell. 2003;4:111-20
165.
Johnson L,Mercer K,Greenbaum D, et al.Somatic activation of the K-ras oncogene causes early onset lung cancer in mice.Nature. 2001;410:1111-6
166.
Dinulescu DM,Ince TA,Quade BJ,Shafer SA,Crowley D,Jacks T.Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.Nat Med. 2005;11:63-70
167.
Aguirre AJ,Bardeesy N,Sinha M, et al.Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.Genes Dev. 2003;17:3112-26
168.
Hingorani SR,Wang L,Multani AS, et al.Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.Cancer Cell. 2005;7:469-83
169.
Izeradjene K,Combs C,Best M, et al.Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas.Cancer Cell. 2007;11:229-43
170.
Tuveson DA,Shaw AT,Willis NA, et al.Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.Cancer Cell. 2004;5:375-87
171.
Braun BS,Archard JA,Van Ziffle JA,Tuveson DA,Jacks TE,Shannon K.Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.Blood. 2006;108:2041-4
172.
Chen X,Mitsutake N,LaPerle K, et al.Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene.Proc Natl Acad Sci U S A. 2009;106:7979-84
173.
Schuhmacher AJ,Guerra C,Sauzeau V,Canamero M,Bustelo XR,Barbacid M.A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition.J Clin Invest. 2008;118:2169-79
174.
Singh M,Lima A,Molina R, et al.Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.Nat Biotechnol. 2010;28:585-93
175.
Perez-Mancera PA,Tuveson DA.Physiological analysis of oncogenic K-ras.Methods Enzymol. 2006;407:676-90
176.
Umanoff H,Edelmann W,Pellicer A,Kucherlapati R.The murine N-ras gene is not essential for growth and development.Proc Natl Acad Sci U S A. 1995;92:1709-13
177.
Johnson L,Greenbaum D,Cichowski K, et al.K-ras is an essential gene in the mouse with partial functional overlap with N-ras.Genes Dev. 1997;11:2468-81
178.
Koera K,Nakamura K,Nakao K, et al.K-ras is essential for the development of the mouse embryo.Oncogene. 1997;15:1151-9
179.
Esteban LM,Vicario-Abejon C,Fernandez-Salguero P, et al.Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development.Mol Cell Biol. 2001;21:1444-52
180.
Plowman SJ,Williamson DJ,O’Sullivan MJ, et al.While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable.Mol Cell Biol. 2003;23:9245-50
181.
Plowman SJ,Arends MJ,Brownstein DG, et al.The K-Ras 4A isoform promotes apoptosis but does not affect either lifespan or spontaneous tumor incidence in aging mice.Exp Cell Res. 2006;312:16-26
182.
Drosten M,Dhawahir A,Sum EY, et al.Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival.EMBO J. 2010;29:1091-104
183.
Potenza N,Vecchione C,Notte A, et al.Replacement of K-Ras with H-Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice.EMBO Rep. 2005;6:432-7
184.
Castellano E,De Las Rivas J,Guerrero C,Santos E.Transcriptional networks of knockout cell lines identify functional specificities of H-Ras and N-Ras: significant involvement of N-Ras in biotic and defense responses.Oncogene. 2007;26:917-33
185.
Castellano E,Guerrero C,Nunez A,De Las Rivas J,Santos E.Serum-dependent transcriptional networks identify distinct functional roles for H-Ras and N-Ras during initial stages of the cell cycle.Genome Biol. 2009;10:R123
186.
Roberts ML,Drosopoulos KG,Vasileiou I, et al.Microarray analysis of the differential transformation mediated by Kirsten and Harvey Ras oncogenes in a human colorectal adenocarcinoma cell line.Int J Cancer. 2006;118:616-27
187.
Zuber J,Tchernitsa OI,Hinzmann B, et al.A genome-wide survey of RAS transformation targets.Nat Genet. 2000;24:144-52
188.
Sweet-Cordero A,Mukherjee S,Subramanian A, et al.An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.Nat Genet. 2005;37:48-55
189.
Vasseur S,Malicet C,Calvo EL, et al.Gene expression profiling by DNA microarray analysis in mouse embryonic fibroblasts transformed by rasV12 mutated protein and the E1A oncogene.Mol Cancer. 2003;2:19
190.
Ohnami S,Aoki K,Yoshida K, et al.Expression profiles of pancreatic cancer cell lines infected with antisense K-ras-expressing adenoviral vector.Biochem Biophys Res Commun. 2003;309:798-803
191.
Kim S,Lee YZ,Kim YS,Bahk YY.A proteomic approach for protein-profiling the oncogenic ras induced transformation (H-, K-, and N-Ras) in NIH/3T3 mouse embryonic fibroblasts.Proteomics. 2008;8:3082-93
192.
Croonquist PA,Linden MA,Zhao F,Van Ness BG.Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells.Blood. 2003;102:2581-92
193.
Brem R,Certa U,Neeb M,Nair AP,Moroni C.Global analysis of differential gene expression after transformation with the v-H-ras oncogene in a murine tumor model.Oncogene. 2001;20:2854-8
194.
Kawano M,Hirano T,Matsuda T, et al.Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.Nature. 1988;332:83-5
195.
Janknecht R,Monte D,Baert JL,de Launoit Y.The ETS-related transcription factor ERM is a nuclear target of signaling cascades involving MAPK and PKA.Oncogene. 1996;13:1745-54
196.
Muda M,Theodosiou A,Rodrigues N, et al.The dual specificity phosphatases M3/6 and MKP-3 are highly selective for inactivation of distinct mitogen-activated protein kinases.J Biol Chem. 1996;271:27205-8
197.
Blackstock WP,Weir MP.Proteomics: quantitative and physical mapping of cellular proteins.Trends Biotechnol. 1999;17:121-7
198.
Malumbres M,Pellicer A.RAS pathways to cell cycle control and cell transformation.Front Biosci. 1998;3:d887-912
199.
Perez de Castro I,Diaz R,Malumbres M, et al.Mice deficient for N-ras: impaired antiviral immune response and T-cell function.Cancer Res. 2003;63:1615-22
200.
Perez de Castro I,Bivona TG,Philips MR,Pellicer A.Ras activation in Jurkat T cells following low-grade stimulation of the T-cell receptor is specific to N-Ras and occurs only on the Golgi apparatus.Mol Cell Biol. 2004;24:3485-96
201.
Wolfman JC,Palmby T,Der CJ,Wolfman A.Cellular N-Ras promotes cell survival by downregulation of Jun N-terminal protein kinase and p38.Mol Cell Biol. 2002;22:1589-606
202.
Eskandarpour M,Kiaii S,Zhu C,Castro J,Sakko AJ,Hansson J.Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.Int J Cancer. 2005;115:65-73
203.
Pruitt K,Der CJ.Ras and Rho regulation of the cell cycle and oncogenesis.Cancer Lett. 2001;171:1-10
204.
Durkin JP,Whitfield JF.Characterization of G1 transit induced by the mitogenic-oncogenic viral Ki-ras gene product.Mol Cell Biol. 1986;6:1386-92
205.
Cai H,Szeberenyi J,Cooper GM.Effect of a dominant inhibitory Ha-ras mutation on mitogenic signal transduction in NIH 3T3 cells.Mol Cell Biol. 1990;10:5314-23
206.
Dobrowolski S,Harter M,Stacey DW.Cellular ras activity is required for passage through multiple points of the G0/G1 phase in BALB/c 3T3 cells.Mol Cell Biol. 1994;14:5441-9
207.
Feig LA,Cooper GM.Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP.Mol Cell Biol. 1988;8:3235-43
208.
Mulcahy LS,Smith MR,Stacey DW.Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells.Nature. 1985;313:241-3
209.
Stacey DW,Kung HF.Transformation of NIH 3T3 cells by microinjection of Ha-ras p21 protein.Nature. 1984;310:508-11
Satoh T,Endo M,Nakafuku M,Akiyama T,Yamamoto T,Kaziro Y.Accumulation of p21ras.GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity.Proc Natl Acad Sci U S A. 1990;87:7926-9
212.
Taylor SJ,Shalloway D.Cell cycle-dependent activation of Ras.Curr Biol. 1996;6:1621-7
213.
Jones SM,Kazlauskas A.Growth-factor-dependent mitogenesis requires two distinct phases of signalling.Nat Cell Biol. 2001;3:165-72
214.
Kumar A,Marques M,Carrera AC.Phosphoinositide 3-kinase activation in late G1 is required for c-Myc stabilization and S phase entry.Mol Cell Biol. 2006;26:9116-25
215.
Stacey D,Kazlauskas A.Regulation of Ras signaling by the cell cycle.Curr Opin Genet Dev. 2002;12:44-6
216.
Takuwa N,Takuwa Y.Regulation of cell cycle molecules by the Ras effector system.Mol Cell Endocrinol. 2001;177:25-33
217.
Sa G,Hitomi M,Harwalkar J,Stacey AW,Gc GC,Stacey DW.Ras is active throughout the cell cycle, but is able to induce cyclin D1 only during G2 phase.Cell Cycle. 2002;1:50-8
218.
Marshall CJ.Small GTPases and cell cycle regulation.Biochem Soc Trans. 1999;27:363-70
219.
Marshall C.How do small GTPase signal transduction pathways regulate cell cycle entry?.Curr Opin Cell Biol. 1999;11:732-6
